Phytocannabinoids and gingival inflammation : Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol
© 2024 The Authors. Journal of Periodontal Research published by John Wiley & Sons Ltd..
OBJECTIVE: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis.
BACKGROUND: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease.
MATERIALS AND METHODS: Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase-1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo-control double-blind randomized study was conducted (56 days) in three groups (n = 90) using dental gel without CBD (group A) and with 1% (w/w) CBD (group B) and corresponding toothpaste (group A - no CBD, group B - with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD.
RESULTS: Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide-induced cells exhibited increased production of pro-inflammatory IL-6 and IL-8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis, with an MIC of 1.5 μg/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days.
CONCLUSIONS: Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of periodontal research - (2024) vom: 05. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jirasek, Petr [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cannabidiol |
|---|
| Anmerkungen: |
Date Revised 05.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/jre.13234 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368011801 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368011801 | ||
| 003 | DE-627 | ||
| 005 | 20240205232213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240205s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jre.13234 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM368011801 | ||
| 035 | |a (NLM)38311974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jirasek, Petr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phytocannabinoids and gingival inflammation |b Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. Journal of Periodontal Research published by John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis | ||
| 520 | |a BACKGROUND: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease | ||
| 520 | |a MATERIALS AND METHODS: Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase-1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo-control double-blind randomized study was conducted (56 days) in three groups (n = 90) using dental gel without CBD (group A) and with 1% (w/w) CBD (group B) and corresponding toothpaste (group A - no CBD, group B - with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD | ||
| 520 | |a RESULTS: Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide-induced cells exhibited increased production of pro-inflammatory IL-6 and IL-8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis, with an MIC of 1.5 μg/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days | ||
| 520 | |a CONCLUSIONS: Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cannabidiol | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a microbiota | |
| 650 | 4 | |a oral hygiene | |
| 650 | 4 | |a periodontium | |
| 650 | 4 | |a phytocannabinoid | |
| 700 | 1 | |a Jusku, Alexandr |e verfasserin |4 aut | |
| 700 | 1 | |a Frankova, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Urbankova, Marketa |e verfasserin |4 aut | |
| 700 | 1 | |a Diabelko, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Ruzicka, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Papouskova, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Chytilova, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Vrba, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Havlasek, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Langova, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Storch, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Voborna, Iva |e verfasserin |4 aut | |
| 700 | 1 | |a Simanek, Vilim |e verfasserin |4 aut | |
| 700 | 1 | |a Vacek, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of periodontal research |d 1966 |g (2024) vom: 05. Feb. |w (DE-627)NLM000130044 |x 1600-0765 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jre.13234 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 02 | ||